Patent US4808610A successfully refreshed from Google Patents.
US4808610A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Mometasone furoate anti-inflammatory cream composition using hexylene glycol
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1986-10-02
•
Granted: 1989-02-28
•
Expires: 2006-10-02
Abstract
Abstract Disclosed is an elegant, stable, self-preserving cream formulation containing mometasone furoate, 9α, 21-dichloro-16α-methyl-1,4-pregnadiene-11β,17α-diol-3,20-dione-17-(2'-furoate), useful as a topical anti-inflammatory product.
Inventors
- 👤 Farah J. Munayyer
- 👤 Joel A. Sequeira
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:51
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K31/00; A61K31/56; A61K31/58; A61P; A61P17/00; A61P17/06; A61P29/00; A61P37/00; A61P37/08
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
102 words
A topical pharmaceutical composition for the treatment of inflammation comprising: (a) 0.01 to 0.25 percent Mometasone Furoate (b) 5 to 20 percent hexylene glycol (c) 1.0 to 5 percent water (d) 2.0 to 10.0 percent white wax (e) 4 to 12 percent of a lipophilic emulsifier having a HLB below 5 (f) 0.7 to 4 percent of a hydrophilic emulsifier having a HLB above 11 (g) 0.2 to 2.0 percent Titanium dioxide (h) 5 to 20 percent aluminum starch octenylsuccinate (i) 40 to 70 percent white petrolatum (j) sufficient acid to adjust the pH of the water to pH 2.5 to ±0.2.
Claim 2
Dependent Claim
102 words
A topical pharmaceutical composition for the treatment of inflammation comprising: (a) 0.01 to 0.25 percent Mometasone Furoate (b) 5 to 20 percent hexylene glycol (c) 1.0 to 5 percent water (d) 2.0 to 10.0 percent white wax (e) 4 to 12 percent of a lipophilic emulsifier having a HLB below 5 (f) 0.7 to 4 percent of a hydrophilic emulsifier having a HLB above 11 (g) 0.2 to 2.0 percent Titanium dioxide (h) 5 to 20 percent aluminum starch octenylsuccinate (i) 40 to 70 percent white petrolatum (j) sufficient acid to adjust the pH of the water to pH 2.5 to ±0.2.
Claim 3
Dependent Claim
99 words
The topical pharmaceutical composition of claim 1 wherein: (a) 0.05 to 0.15 percent Mometasone Furoate (b) 9 to 15 percent hexylene glycol (c) 2 to 4 percent water Purified (d) 4 to 6 percent white wax (e) 6 to 10 percent of a lipophilic emulsifier having a HLB below 5 (f) 1.2 to 2.5 percent of a hydrophilic emulsifier having a HLB above 11 (g) 0.75 to 1.25 percent titanium dioxide (h) 8 to 12 percent aluminum starch octenylsuccinate (i) 50 to 60 percent white petrolatum (j) sufficient acid to adjust the pH of the water to pH 2.5±0.2.
Claim 4
Dependent Claim
26 words
The topical pharmaceutical composition of claim 1 wherein the acid utilized to adjust the pH of the water of phosphoric acid, hydrochloric acid or acetic acid.
Claim 5
Dependent Claim
27 words
The topical pharmaceutical composition of claim 3 wherein the lipophilic emulsifier is propylene glycol stearate, ethylene glycol monolaurate, ethylene glycol monostearate, propylene glycol monolaurate or glyceryl monoricinolate.
Claim 6
Dependent Claim
32 words
The topical pharmaceutical composition of claim 4 wherein the hydrophilic emulsifier is stearyl alcohol and ceteareth-20, polyethylene glycol monolaurate, polyethylene glycol distearate, P.O.E. cetyl alcohol, P.O.E. sorbitan monostearate or P.O.E. sorbitan monooleate.
Claim 7
Dependent Claim
77 words
The topical pharmaceutical composition for the treatment of inflammation comprising: ______________________________________
mg/gram
______________________________________
(a) Mometasone Furoate 1.0
(b) Hexylene Glycol NF 120
(c) Water Purified USP 30
(d) White Wax NF 50
(e) Propylene Glycol Stearate
80
(f) Stearyl Alcohol and Ceteareth-20
70
(Promulgen-G)
(g) Titanium Dioxide USP 10
(h) Aluminum Starch Octenylsuccinate
100
(i) White Petrolatum USP 539
(j) Sufficient Phosphoric Acid NF to
adjust the pH of the water to pH
2.5 ± 0.2.
______________________________________
Claim 8
Dependent Claim
77 words
The topical pharmaceutical composition for the treatment of inflammation comprising: ______________________________________
mg/gram
______________________________________
(a) Mometasone Furoate 1.0
(b) Hexylene Glycol NF 120
(c) Water Purified USP 30
(d) White Wax NF 50
(e) Propylene Glycol Stearate
80
(f) Stearyl Alcohol and Ceteareth-20
70
(Promulgen-G)
(g) Titanium Dioxide USP 10
(h) Aluminum Starch Octenylsuccinate
100
(i) White Petrolatum USP 539
(j) Sufficient Phosphoric Acid NF to
adjust the pH of the water to pH
2.5 ± 0.2.
______________________________________
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-02-28 | 1992-08-29 | 1993-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-02-28 | 1996-08-29 | 1997-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-02-28 | 2000-08-29 | 2001-02-28 | $7700.00 | Window Closed / Lapsed |